Skip to main content

Table 1 Baseline characteristics of the subjects tested in the present study

From: Cybernic treatment with wearable cyborg Hybrid Assistive Limb (HAL) improves ambulatory function in patients with slowly progressive rare neuromuscular diseases: a multicentre, randomised, controlled crossover trial for efficacy and safety (NCY-3001)

Characteristic Group A (N = 13) Group B (N = 11)
Age (years) 56.0 (13.2) 55.5 (7.8)
 < 65 10 (76.9%) 9 (81.8%)
 ≥ 65 3 (23.1%) 2 (18.2%)
Female sex 6 (46.2%) 6 (54.5%)
Height (m) 1.642 (0.085) 1.643 (0.099)
Weight (kg) 54.97 (9.16) 59.15 (14.67)
Body mass index (kg/m2) 20.38 (2.85) 21.67 (3.89)
Blood pressure (mm Hg) 128.7 (8.5)/84.7 (13.6) 118.2 (15.6) / 72.9 (10.0)
Heart rate (beats/min) 75.0 (9.3) 75.6 (8.0)
Abnormal ECG 4 (30.8%) 5 (45.5%)
Other neurological abnormal findings 0 (0%) 0 (0%)
Muscle CT findings consistent with the target disease 13 (100%) 11 (100%)
Previous diseases 0 0
Concurrent diseases 12 (92.3%) 9 (81.8%)
Number of targeted neuromuscular diseases   
 Spinal muscular atrophy 3 2
 Spinal bulbar muscular atrophy 2 0
 Amyotrophic lateral sclerosis 1 0
 Charcot Marie Tooth disease 1 2
 Myotonic dystrophy 0 2
 Distal myopathy with RV 0 1
 Distal myopathy, Myoshi 2 2
 FSH-type muscular dystrophy 2 1
 Other limb girdle-type muscular dystrophy 1 1
 Sporadic inclusion body myositis 1 0
 Concomitant treatment, medication 13 (100%) 11 (100%)
 Other rehabilitation programs 9 (69.2%) 8 (72.7%)
 Outpatient during treatment periods 8 (61.5%) 2 (18.2%)
2MWT (metres) 63.258 (30.457) 67.257 (25.508)
Barthel index (total score: 0–100) 75.4 (21.0) 84.5 (11.9)
Total Manual Muscle Test (MMT) scores (0–60) 31.12 (5.57) 30.59 (3.64)
  1. Data are means (SD) or numbers (%); SD, standard deviation; RV and FSH denote Rimmed Vacuole and Facioscapulohumeral, respectively